2. Gene
  3. Kit - KIT proto-oncogene receptor tyrosine kinase Gene

Kit - KIT proto-oncogene receptor tyrosine kinase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：K IT 原癌基因 受体酪氨酸激酶

种属: Mus musculus

同用名: W; Bs; Fdc; Ssm; SCO1; SCO5; SOW3; CD117; c-KIT; Tr-kit; Gsfsco1; Gsfsco5; Gsfsow3

基因 ID: 16590 | 基因类型: protein coding

关于 Kit

Chromosome 5: 75,735,576-75,817,382 forward strand.GRCm39:CM000998.3

This gene has 8 transcripts (splice variants), 206 orthologues, 53 paralogues and is associated with 222 phenotypes. Broad expression in lung adult (RPKM 39.), cerebellum adult (RPKM 19.6) and 25 other tissues.

功能概要

c-Kit 原癌基因是猫逆转录病毒 (v-Kit) 转化基因的细胞同系物。 c-Kit 蛋白包括蛋白激酶跨膜受体的特征。已发现该基因编码不同亚型的可变剪接转录物变体。 [RefSeq 提供，2008 年 7 月]

The c-Kit proto-oncogene is the cellular homolog of the transforming gene of a feline retrovirus (v-Kit). The c-Kit protein includes characteristics of a protein kinase transmembrane receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Kit 基因产物(2)

mRNA Protein Name
NM_001122733.1 NP_001116205.1 mast/stem cell growth factor receptor Kit isoform 1 precursor
NM_021099.3 NP_066922.2 mast/stem cell growth factor receptor Kit isoform 2 precursor

Kit 蛋白结构

ig

ig: pfam00047 (216 - 307)

Ig

Ig: cd00096 (229 - 233)

Ig

Ig: cd00096 (243 - 247)

Ig

Ig: cd00096 (275 - 279)

Ig

Ig: cd00096 (299 - 305)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (313 - 413)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (313 - 319)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (323 - 328)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (331 - 341)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (345 - 352)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (354 - 357)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (360 - 365)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (374 - 383)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (390 - 398)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (401 - 412)

Ig

Ig: cd00096 (428 - 504)

Ig

Ig: cd00096 (439 - 443)

Ig

Ig: cd00096 (472 - 480)

Ig

Ig: cd00096 (490 - 495)

PTKc_Kit

PTKc_Kit: cd05104 (555 - 929)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 979 a.a.
蛋白主名 其他名称

mast/stem cell growth factor receptor Kit

Dominant white spotting

SCFR

Steel Factor Receptor

belly-spot

c-kit proto-oncogene protein

dominant spotting

kit oncogene

proto-oncogene c-Kit

proto-oncogene tyrosine-protein kinase Kit

spotted sterile male

tyrosine-protein kinase Kit

重组 Kit 蛋白

目录号 产品名 蛋白编号 纯度
HY-P72879 CD117/c-Kit Protein, Mouse (523a.a, HEK293, Fc) P05532 (S25-T523) ≥95%
HY-P72880 CD117/c-Kit Protein, Mouse (HEK293, His) P05532 (S25-T523) ≥95%
HY-P78712 CD117/c-kit Protein, Mouse (495a.a, HEK293, Fc) P05532-2 (S25-T519) ≥95%

相关产品

Approval
生物活性分子 (28)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10201 Sorafenib 99.92% 是
HY-10981 Lenvatinib Inhibitor 99.84% 是
HY-16749 Pexidartinib 99.64% 是
HY-10331 Regorafenib 99.93% 是
HY-15463 Imatinib 99.95% 是
HY-13016 Cabozantinib 99.96% 是
HY-10230 Midostaurin 99.95% 是
HY-10208 Pazopanib 99.91% 是
HY-10201A Sorafenib Tosylate 99.91% 是
HY-50946 Imatinib Mesylate 99.98% 是
HY-101561 Avapritinib Inhibitor 99.94% 是
HY-10209 Masitinib 99.98% 是
HY-112306 Ripretinib 99.33% 是
HY-10981A Lenvatinib mesylate Inhibitor 99.86% 是
HY-16749A Pexidartinib hydrochloride 99.86% 是
HY-12009 Pazopanib Hydrochloride 99.88% 是
HY-13308 Regorafenib Hydrochloride 99.58% 是
HY-10331A Regorafenib monohydrate 99.96% 是
HY-12044 Cabozantinib S-malate 99.90% 是
HY-13904 Flumatinib Inhibitor 99.94% 否
HY-10209A Masitinib mesylate 99.83% 是
HY-13311A Infigratinib phosphate Inhibitor 99.74% 是
HY-10330A Toceranib phosphate Inhibitor 98.54% 否
HY-10330 Toceranib Inhibitor 96.86% 否
HY-B1684 Mebrofenin 99.88% 否
HY-10331B Regorafenib mesylate / 否
HY-13016A Cabozantinib hydrochloride / 否
HY-50946R Imatinib Mesylate (Standard) / 否
Clinical Phase
生物活性分子 (28)
目录号 产品名 作用方式
纯度 Phase
HY-13905 Flumatinib mesylate Inhibitor 99.87% Phase 4
HY-50905 Dovitinib Inhibitor 99.94% Phase 3
HY-10205 Cediranib 99.58% Phase 3
HY-16961 Sitravatinib Inhibitor 99.59% Phase 3
HY-145557 Bezuclastinib Inhibitor 98.59% Phase 3
HY-136256 Vimseltinib Inhibitor 99.08% Phase 3
HY-13049 Cediranib maleate 99.95% Phase 3
HY-10228 Motesanib Inhibitor 99.96% Phase 3
HY-108713 Famitinib 98.43% Phase 3
HY-124526 Chiauranib Inhibitor 99.28% Phase 3
HY-10207 Dovitinib lactate Inhibitor 99.62% Phase 3
HY-10229 Motesanib Diphosphate Inhibitor 99.64% Phase 3
HY-152839 Elenestinib Inhibitor 98.82% Phase 3
HY-16961A Sitravatinib malate Inhibitor / Phase 3
HY-B0062 Dovitinib lactate hydrate Inhibitor / Phase 3
HY-108713A Famitinib malate / Phase 3
HY-13024 Rebastinib 99.91% Phase 2
HY-109086 Edicotinib Inhibitor 98.78% Phase 2
HY-10206 Amuvatinib 99.47% Phase 2
HY-10202 Tandutinib 99.48% Phase 2
HY-109190 Seralutinib Inhibitor 99.77% Phase 2
HY-10527 Telatinib Inhibitor 99.60% Phase 2
HY-10202A Tandutinib hydrochloride 99.78% Phase 2
HY-10527C Telatinib mesylate Inhibitor 99.46% Phase 2
HY-10206A Amuvatinib hydrochloride Inhibitor / Phase 2
HY-10204 OSI-930 98.57% Phase 1
HY-12010 BMS-599626 Hydrochloride Inhibitor 99.68% Phase 1
HY-10251 BMS-599626 Inhibitor / Phase 1
抗体抑制剂 (1)
目录号 产品名 作用方式
纯度 Phase
HY-P99462 Barzolvolimab Inhibitor 99.78% Phase 2
Pre-clinical Phase
生物活性分子 (88)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-10514 BX795 99.17% 否
HY-101443 ISCK03 Inhibitor 99.50% 否
HY-131339 SP-96 Inhibitor 99.42% 否
HY-10501 SU14813 Inhibitor 99.63% 否
HY-G0017 N-Desmethyl imatinib 99.16% 否
HY-112802 AZD3229 Inhibitor 99.69% 否
HY-13894 Tyrphostin AG1296 99.69% 否
HY-13838 PLX647 Inhibitor 99.79% 否
HY-132166 M4205 Inhibitor 99.47% 否
HY-10873 N-Desethyl Sunitinib 99.63% 否
HY-10408 Ki20227 Inhibitor 99.17% 否
HY-15240 c-Kit-IN-1 Inhibitor 98.83% 否
HY-10501A SU14813 maleate Inhibitor 99.04% 否
HY-101219 VEGFR-IN-1 Inhibitor 98.42% 否
HY-112452 SU11652 99.06% 否
HY-I0678 Regorafénib N-oxyde (M2) 98.27% 否
HY-103274 PD180970 99.27% 否
HY-15463S1 Imatinib-d4 99.97% 否
HY-15813 FIIN-1 Inhibitor 99.11% 否
HY-148794 Risvodetinib Inhibitor 99.21% 否
HY-13493 AC710 Inhibitor 98.56% 否
HY-112615 NAMPT inhibitor-linker 1 98.08% 否
HY-13016S Cabozantinib-d6 98.14% 否
HY-103032 Multi-kinase inhibitor 1 Inhibitor 99.34% 否
HY-112616 NAMPT inhibitor-linker 2 Inhibitor 98.11% 否
HY-10981S Lenvatinib-d4 Inhibitor 99.59% 否
HY-133980A O-Demethyl Lenvatinib hydrochloride 95.54% 否
HY-138813 N-Desethyl Sunitinib hydrochloride 99.77% 否
HY-18302 c-Kit-IN-5-1 Inhibitor 98.16% 否
HY-18179 AZD2932 Inhibitor 99.04% 否
HY-112802A AZD3229 Tosylate Inhibitor 99.80% 否
HY-10208S Pazopanib-d6 ≥98.0% 否
HY-10230S Midostaurin-d5 Inhibitor ≥98.0% 否
HY-12009S Pazopanib-13C,d3 hydrochloride 97.51% 否
HY-123450 S116836 99.65% 否
HY-133980 O-Demethyl Lenvatinib / 否
HY-136201 Sodium Glucoheptonate ≥98.0% 否
HY-15198 KG5 Inhibitor 99.79% 否
HY-15463S Imatinib-d8 99.85% 否
HY-15463S2 Imatinib-d3 hydrochloride 95.19% 否
HY-156619 Labuxtinib Inhibitor 99.76% 否
HY-160765 WNTinib / 否
HY-18317 JNJ-38158471 Inhibitor 97.02% 否
HY-101034 CHMFL-ABL/KIT-155 / 否
HY-128589 CHMFL-KIT-033 Inhibitor / 否
HY-128602 c-Kit-IN-2 Inhibitor / 否
HY-10873S N-Desethyl Sunitinib-d5 / 否
HY-10201S2 Sorafenib-13C,d3 98.35% 否
HY-10208S1 Pazopanib-13C,d3 / 否
HY-10331S Regorafenib-d3 ≥98.0% 否
HY-10331S1 Regorafenib-13C,d3 / 否
HY-10981S1 Lenvatinib-d5 Inhibitor / 否
HY-110071 APcK110 Inhibitor / 否
HY-110272 Vatalanib succinate Inhibitor / 否
HY-110293 CHMFL-FLT3-122 / 否
HY-117873 KBP-7018 Inhibitor / 否
HY-13016S1 Cabozantinib-d4 / 否
HY-131275 Imatinib Impurity E 96.05% 否
HY-132451S (R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit / 否
HY-13342AS Apatinib-d8 free base 92.56% 否
HY-13645 Henatinib Inhibitor / 否
HY-13838A PLX647 dihydrochloride Inhibitor / 否
HY-13904S Flumatinib-d3 Inhibitor / 否
HY-139996 Pomalidomide-C5-Dovitinib / 否
HY-143894 FLT3-IN-11 Inhibitor / 否
HY-143895 FLT3-IN-12 Inhibitor / 否
HY-147864 c-Fms-IN-12 / 否
HY-149019 Antitumor agent-70 / 否
HY-149415 Multi-kinase-IN-5 Inhibitor / 否
HY-150026 Multi-kinase-IN-2 / 否
HY-156470 Multi-kinase-IN-6 / 否
HY-15814 HG-7-85-01 99.94% 否
HY-160689 GW694590A Inhibitor / 否
HY-18949 JI6 Inhibitor / 否
HY-50905S Dovitinib-d8 Inhibitor / 否
HY-G0017A N-Desmethyl imatinib mesylate / 否
HY-G0017S1 N-Desmethyl imatinib-d4 / 否
HY-I0678S Regorafénib N-oxyde-d3 (M2) / 否
HY-I0678S1 Regorafénib N-oxyde (M2)-13C,d3 / 否
HY-RS07319 KIT Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS07320 Kit Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS07321 Kit Rat Pre-designed siRNA Set A Pre-designed Sets / 否
HY-10330S Toceranib-d8 Inhibitor / 否
HY-10981S2 Lenvatinib-15N,d4 Inhibitor / 否
HY-116116 Tafetinib Inhibitor / 否
HY-13493A AC710 Mesylate Inhibitor / 否
HY-W143698 PDGFRα kinase inhibitor 2 Inhibitor / 否
HY-111947 c-Fms-IN-6 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Kit NCBI NCBI:3815
Canis familiaris Kit NCBI NCBI:403811
Rattus norvegicus Kit NCBI NCBI:64030
Macaca mulatta Kit NCBI NCBI:696759
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z